ALX-0600
CL0600-008
Phase 2 small_molecule completed
Quick answer
ALX-0600 for Crohn's Disease is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Crohn's Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed